Valuation: PTC Therapeutics, Inc.

Market Cap 6.91B 6.04B 5.55B 5.17B 9.82B 658B 9.96B 66.65B 25.91B 323B 25.94B 25.38B 1,115B P/E 2026 *
94x
P/E 2027 * 33.4x
Enterprise Value 5.13B 4.48B 4.12B 3.84B 7.28B 488B 7.39B 49.45B 19.22B 240B 19.24B 18.83B 827B EV / Sales 2026 *
4.37x
EV / Sales 2027 * 3.86x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day+2.41%
1 week-1.33%
Current month+2.13%
1 month+21.30%
3 months+22.93%
6 months+8.56%
Current year+9.68%
1 week 80.21
Extreme 80.21
84.37
1 month 69.74
Extreme 69.74
87.03
Current year 61.43
Extreme 61.43
87.03
1 year 43.18
Extreme 43.175
87.5
3 years 17.53
Extreme 17.53
87.5
5 years 17.53
Extreme 17.53
87.5
10 years 4.03
Extreme 4.03
87.5
Manager TitleAgeSince
Chief Executive Officer 54 21/03/2023
Director of Finance/CFO 41 12/07/2023
Chief Tech/Sci/R&D Officer - 30/09/2017
Director TitleAgeSince
Chairman 74 31/10/2004
Chairman 80 30/03/1998
Director/Board Member 65 30/11/2005
Date Insider Type Main position Quantity % Market Cap.
06-25Fiscal year

Chief Technology Officer

24,390 0.0294%
06-24Fiscal year

Chief Technology Officer

62,880 0.0758%
06-21Fiscal year

Chief Technology Officer

71,247 0.0859%
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%-1.33%+69.78%+101.18% 6.91B
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+32.57%+24.89% 338B
-0.56%+0.96%+41.67%+39.35% 299B
-0.08%+1.30%+32.15%+44.48% 291B
-1.54%+2.81%-25.35%-39.61% 222B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +2.13%+3.98%+35.58%+62.52% 369.93B
Weighted average by Cap. +2.25%+5.52%+42.36%+83.34%

Financials

2026 *2027 *
Net sales 1.17B 1.03B 943M 879M 1.67B 112B 1.69B 11.32B 4.4B 54.91B 4.4B 4.31B 189B 1.31B 1.15B 1.05B 983M 1.86B 125B 1.89B 12.66B 4.92B 61.43B 4.93B 4.82B 212B
Net income 65.46M 57.22M 52.59M 49.02M 92.97M 6.23B 94.38M 631M 245M 3.06B 246M 240M 10.56B 178M 156M 143M 133M 253M 16.94B 256M 1.72B 667M 8.33B 668M 653M 28.69B
Net Debt -1.78B -1.56B -1.43B -1.34B -2.53B -170B -2.57B -17.2B -6.69B -83.49B -6.7B -6.55B -288B -1.84B -1.61B -1.48B -1.38B -2.61B -175B -2.65B -17.75B -6.9B -86.13B -6.91B -6.76B -297B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
02/07/26 US$83.31 +2.41% 6,778,019
01/07/26 US$81.35 -0.27% 1,221,573
30/06/26 US$81.57 0.00% 2,375,631
29/06/26 US$81.57 -3.39% 4,294,986
26/06/26 US$84.43 -0.09% 3,903,105
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
83.31USD
Average target price
93.93USD
Spread / Average Target
+12.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock